Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review
Pfizer will no longer invest in the development of its oral GLP-1 drug danuglipron after the pharma detected a potential...
Safety
Chronic Kidney Disease: Challenges In Medication Safety
The extent by which potentially inappropriate medications or monitoring is given to people with CKD has not been sufficiently evaluated,...
Kidney Group Unveils Risk Campaign During National Safety Month
Innovation and Engagement Transform Infection Prevention and Disaster Readiness Government Leaders and Care Providers Must Involve Patients in Continuity Plans...
